- About UCB US
- R & D
- Contact Us
UCB’s interactions with heathcare professionals are a vital component of ensuring that UCB delivers innovative medicines to patients. These interactions take on many forms, including clinical trial participation, consulting and advisory services, and on-going informational exchange with UCB colleagues. UCB also provides educational materials for healthcare professionals to benefit the delivery of healthcare to patients. To ensure that our interactions remain consistent and appropriate, UCB has adopted the PhRMA Code on Interactions with Heathcare Professionals.
On February 1, 2013, the U.S. Centers for Medicare and Medicaid Services (CMS) announced the final requirements for the National Physician Payment Transparency Program (also known as the “Sunshine Act” or “Open Payments”), creating greater financial transparency into the interactions between pharmaceutical companies, physicians and teaching hospitals. Effective August 1, 2013, pharmaceutical, biological, and medical device companies began tracking required types of payments and transfers of value for the purpose of providing an annual disclosure report to CMS. The first “Open Payments” disclosure report was publically posted September 30, 2014, on the CMS website. You can view the posted information on the Open Payments website and obtain additional information at this site: http://www.cms.gov/openpayments/index.html
UCB is committed to complying with all federal and state transparency and disclosure requirements and has been posting physician payments information since 2012, in advance of the effective date of the Federal requirements taking effect. As new industry and government standards emerge, UCB will continue to ensure that our policies are in alignment.
If you have any questions about transparency initiatives or reports, please contact the UCB Compliance Department (Transparency Support) at email@example.com.